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ABSTRACT  
Background: Sarcomas are malignant neoplasms that occur anywhere in the human 
body. Though their occurrence in the head and neck region is rare vis-a-vis other 
malignancies, their presence is of tremendous concern due to their often grave prognosis.  
Objective: To determine the pattern of occurrence, histopathologic types of 
maxillofacial sarcomas and their proportion to other malignant neoplasms of 
this region based on archival material accumulated over 10 years (2000-2009).  
Design: A combined retrospective and prospective cross-sectional study.
Setting: The University of Nairobi Dental Hospital (UNDH). 
Subjects: All cases with a diagnosis of sarcoma registered between 2000-2009 were evaluated.  
Results: Of the 528 malignancies recorded over the ten-year period, 427 (80.9%) were of 
epithelial origin while 101 (19.1%) were sarcomas. Patients with epithelial malignancies 
were older (54.16 ± 15.94 years) than patients with sarcomas (31.73 ± 16.78) with the 
differences having been statistically significant. Osteosarcoma was the most commonly 
occurring sarcoma (29.7%), followed by Kaposi’s sarcoma (KS) (28.7%), fibrosarcoma (FBS) 
(18.8%), and rhabdomyosarcoma (RMS) (9.9%). Sarcomas peaked in the third decade with 
70% occurring below the age of 40 years. The maxilla and the mandible were the most 
afflicted sites in the maxillofacial region accounting for 52%. The patients on average 
presented to medical personel about nine months after noticing the lesion with the most 
frequent complaint having been swelling. 
Conclusion: The present study confirms the relative rarity of maxillofacial sarcomas. 
It also provides data on the histopathologic types and demographic characteristics of 
maxillofacial sarcomas in a select Kenyan population. This information is a contribution 
to the comprehensive documentation of sarcomas that occur globally and is useful in the 
provision of baseline data upon which future prospective analytical protocols may arise. 
INTRODUCTION  
Whole body sarcomas are relatively rare. In the United 
States, sarcomas account for approximately 1% of all 
malignancies with 5 to 15% of these lesions occurring in 
the head and neck region (1). In Nigeria, a retrospective 
study by Arotiba et al.  reported 58 sarcomas (12.37%) 
out of 469 orofacial malignancies (2). Although head 
and neck sarcomas occur infrequently in adults, in 
the paediatric population one in three sarcomas 
will occur in the head and neck region. Most head 
and neck sarcomas are of the soft-tissue type with 
only 20% being of bony or cartilaginous origin (3). 
 There exist a limited number of reports on 
individual sarcomas occurring in the maxillofacial 
region. Most reports are centred on the head and 
neck region rather than the more limited maxillofacial 
area. In general, studies on head and neck sarcomas 
are rare in the English literature. Further, the small 
number of patients with head and neck sarcomas 
makes it difficult for prospective studies to be 
undertaken. Chindia et al revealed that, of the 10,897 
whole body neoplasms reported between 1982-1991 
at the Kenyatta National Hospital in Kenya, 985 
were sarcomas among which 16% were found in 
the head and neck region (4). A clinico-pathologic 
study by Adebayo et al in Nigeria reported that 20% 
of maxillofacial malignancies were sarcomas with a 
slight female to male predilection of 1.3:1 (5,6). 
Bone sarcomas: Osteosarcoma is the most common 
primary malignancy of bone, with a reported 
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incidence of 1:100,000 (7). August et al estimated 
that less than 4% of all recorded osteogenic sarcomas 
occur in the jaw. The mandible and maxilla are the 
predominate locations of head and neck osteosarcoma 
(HNOS), although extragnathic bone as well as 
soft tissues sites may be affected (10). Adebayo 
et al. Chidzonga et al and Chindia et al found the 
mandible to have been the most common site affected 
(5,11,12). The five-year disease-specific survival rate 
for patients with HNOS has been poor, with most 
studies reporting survival rates of 23-37% (7-9,13,14). 
Soft tissue sarcomas: Soft-tissue sarcomas (STS) are 
an uncommon but important problem in head and 
neck oncology. STS constitute less than 1% of all 
head and neck malignancies and include many 
histologic subtypes of varied biological behaviour 
(1). Fibrosarcomas (FBS) are relatively uncommon 
tumours and account for 12-19% of soft tissue 
sarcomas. More than half of all the tumours arise in 
the lower extremities; approximately 10% occur in 
the head and neck, most commonly in the sinonasal 
tract and neck. FBS may arise in patients of any 
age and a slight male predominance exists. In the 
African series, no gender bias has been noted with 
the mandible having been the most common site. Age 
ranges are similar to those in the western series (5,11). 
 Since the outbreak of AIDS, Kaposi’s sarcoma 
(KS) has become the most common type of 
intra-oral sarcoma. Before the outbreak of HIV 
infection, KS was a rare form of sarcoma and 
literature from New South Wales showed an 
overall incidence of 0.47/million persons. With 
the advent of HIV infection, the occurrence of 
KS has rapidly increased and has even reached 
epidemic proportions in some regions where HIV 
infection is high. There are some studies which 
have shown that up to 24% of HIV infected 
patients have KS (4). Butt et al in an evaluation of 
oral manifestations of HIV infection at a Kenyan 
provincial hospital documented 13% of oral KS 
among 61 patients aged 16 years and above (15). 
Rhabdomyosarcoma (RMS): A tumour of skeletal muscle 
origin, is the most common STS in children and 
adolescents affecting the head and neck (16). RMS 
has three distinct histopathologic types: alveolar, 
embryonal and pleomorphic. The embryonal type 
accounts for 70% of all cases and is particularly 
common in the oral and peri-oral region (17). In a 
review of 88 cases in Zimbabwe, Chidzonga et al 
reported that RMS was the second most common 
sarcoma predominantly in boys and afflicting mainly 
the maxilla (11). Adebayo et al reported RMS to 
have been the third most common sarcoma behind 
osteosarcoma and chondrosarcoma. Most were noted 
to occur in the cheek with 50% of the cases in the 
first decade (5). 
Other sarcomas: Several other sarcomas exist but from 
the literature they occur rarely in the maxillofacial 
region. There is need for basic research to better 
understand these tumours with regard to prompt 
intervention and clinical management. The aim of this 
study, therefore was to determine the demographic 
pattern of occurrence and histopathologic types of 
maxillofacial sarcomas as well as their proportion 
to other malignancies at a Nairobi centre, Kenya. 
MATERIALS AND METHODS  
The study was carried out at the histopathology 
laboratory of the University of Nairobi Dental Hospital 
(UNDH).
 Data were recorded using a specially designed 
chart. The data collected included demographic patterns, 
clinical presentation and the histopathologic variants as 
previously reported of all maxillofacial malignancies seen 
over a ten-year period (2000 to 2009). Only the histop-
athology reports from the UNDH laboratory were used. 
Recording of individual sarcomas was done utilising the 
simplified clinical classification of the University of Texas 
M. D. Anderson cancer centre. The  demographic  patterns 
and clinical presentation information were accessioned 
from the patients’ hospital files. Case definition for the 
study was any sarcoma diagnosed for the first time at 
the Oral Pathology Laboratory at the UNDH. Recurrent 
diseases were excluded. Cancer cases were coded 
according to the International Classification of  Diseases. 
Data were analysed using the statistical package for social 
sciences version 11.5 with the main outcome measures 
having been the demographic pattern of occurrence and 
histopathologic variants of maxillofacial sarcomas.  
RESULTS 
Demographic distribution of sarcomas as compared 
to other malignancies of the maxillofacial region 
showed that over the ten-year period, 525 cases of 
malignant neoplasm were recorded among which 
424 (80.9%) were of epithelial origin while 101 
(19.1%) were sarcomas. There were more males 
273 (52%) than females 252 (48%). The age range 
was between 3 to 90 years with a mean of 49.64 
years (SD±18.45 years). Patients with epithelial 
malignancies were older, 54.16 years ±15.94 (95%CI 
52.52 - 55.75), than those with sarcomas who had 
an average age of occurrence at 31.73 years±16.785 
(95%CI 28.3735.10). The difference was statistically 
significant (Mann Z= -10. 266, P<0.01 (0.000). More 
males had epithelial malignancies than females while 
there were more females with sarcomas. However, 
the difference was not statistically significant 
(X2=2.09, p=0.15). The distribution of maxillofacial 
malignancies by year is illustrated in Fig. 1. 
Age distribution of sarcomas: Among the 101 cases 
of sarcoma, 46 (45.5%) occurred in males while 
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55 (54.5%) were found in females with an overall 
age range of 3 to 90 years. The 20 to 29 year-old 
age group was the most commonly affected with 
28 cases and a significant proportion of sarcomas 
(70.29%) occurred in patients less than 40 years of 
age. There was no statistically significant difference 
in the ages of male (31.19±17.99 years) and female 
(32.20±15.84 years) patients at first presentation 
(p=0.770). Table 1 illustrates the distribution of the 
sarcoma sub-types among the various age groups.
Clinical presentation, site distribution and tumour 
type: Of the 101 sarcomas recorded, 98 had the site 
of tumour occurrence indicated. The maxilla was the 
most commonly affected site with 26 sarcomas while 
25 were found in the mandible and 17 occurred in 
the palate. Eleven cases were found in the tongue 
so that cumulatively, these four sites contributed to 
80.5% of the sarcomas. Table 2 shows the distribution 
of the various sarcoma sub-types according to site. 
Of all the sarcoma cases analysed, 73 had information 
regarding the duration between when the patient first 
noticed the condition to when they first presented 
to medical personnel. The average duration was 
9.9 months (SD=14.91). One case was diagnosed 
incidentally on routine medical examination while one 
other patient presented after nine years. For patients 
who presented with sarcomas, 51 clinical records 
were located. All but one presented with swelling 
of the affected site. Other prominent features were 
pain (37%), bleeding (19%), mobility of teeth (12%), 
limited mouth opening (10%) and paraesthesia (10%). 
A case of osteosarcoma was diagnosed incidentally 
during routine dental examination. Concerning the 
tissue of origin, 32 sarcomas (31.68%) were of bony or 
cartilaginous origin while 69 (68.32%) were of soft tissue 
origin. More females (54.45%) were affected than males 
(45.54%). However, the differences were not statistically 
significant. {X2=1.222; 1df; p>0.05 (p=0.269)}.
Hard tissue sarcomas: Among the osteosarcomas 
reviewed, the most commonly affected age group 
was the 10-19 years with most (83.33%) occurring 
below 40 years of age. The overall mean age at 
diagnosis was 28.40 years and a statistically significant 
difference (p=0.019) was observed between the 
mean age at first presentation in men (21.18±6.91 
years) and females (32.58±17.24 years). Among the 
sub-types of osteosarcoma, 14 (46.7%) were of the 
osteoblastic sub-type, nine (30%) were fibroblastic 
while seven (23.3%) were chondroblastic. More 
females were affected (63.33%) than males (36.67%) 
with the same trend having been seen among 
the sub-types. However, the difference was not 
statistically significant (X2=0.532; p>0.05 (p=0.892). 
Soft tissue sarcomas: Ten lesions of RMS were reviewed 
which occurred in cases with an overall mean age 
at diagnosis of 17.77 years with no statistically 
significant difference observed in the ages of males 
(17.50±20.46 years) and females (17.88±9.40 years) 
at first presentation (p=0.291). Five of these were 
of the pleomorphic sub-type, three embryonal 
and one was of the alveolar sub-type. An equal 
number of males and females were affected. More 
males were affected by the embryonal sub-type 
while more females were affected by the alveolar 
and pleomorphic RMS. However, the differences 
were not statistically significant {X2=1.48f, p>0.05 
(p=1.000)}. Of the eight cases that had the age 
indicated four were found in the zero to nine year-
old age bracket. One case of pleomorphic  
RMS occurred in the 50-59-year-old age bracket. 
Majority (87.5%) were seen below 30 years of age. 
 Over the ten-year period 19 cases of FBS were 
recorded among which ten (52.63%) occurred in 
females while nine (47.37%) were in males. The 
mean age at first diagnosis was 32.16 years with 
no statistical difference noted in the ages of men 
(39.56±23.85) and women (25.50±10.80) at first 
diagnosis (p=0.115). The 20-29 year-old age group 
was the most commonly affected (n=9) with 73.68% 
of the cases occurring below the age of 40 years. 
 KS was the second most frequently occurring 
maxillofacial sarcoma recorded over the ten-year 
period (n=29). Majority (72.41%) were found between 
the ages of 20-50 years. The overall mean age was 
36.68 years with no statistical difference (p=0.087) 
in the age at first presentation of men (33.75±10.80 
years) and women (38.29±15.89 years). There was 
an almost equal distribution between the genders 
with 15 (51.72%) in males and 14 (48.28%) seen in 
females. 
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Figure 1
Yearly distribution of maxillofacial malignancies
Table 1
Distribution of sarcoma subtypes according to the age groups 
Neoplasm  Age of patient in years 
 0-19  20-39  40-59  60+ Total 
Osteosarcoma    10    15    2    3    30     
Chondrosarcoma    0    1    1    0    2     
MFH    0    1    0    0    1     
Fibrosarcoma    3    11    3    2    19     
Rhabdomyosarcoma    5    3    1    0    9     
Angiosarcoma       1  0    0     0  1     
Kaposi’s sarcoma    2    15    10    2    29     
Haemangiopericytoma (H PT)    0    1    0    0    1     
Haemangioendothelioma (HED)    0    2    0    1    3     
Liposarcoma    0    1    0    1    2     
Unclassified    0    0    0    1    1     
Total    21    50    17    10  98
Table 2
Distribution of sarcoma types by site
Neoplasm      Site 
 Max  mand  cheek  tongue  FOM lip  palate ging/alv MSG  ill def  Total 
Osteosarcoma   15    12     -    -    -       -    -    - - 1    28
Chondrsarcoma 1      1    -    -    -    -      -    -    -    - 2   
RMS    3    2    2    1    -       - - - -      2    10
FBS    5    8    3    -      -      1    -    -      - 1    18
MFH    -      -      1      -       -    1 - - -   1 
Angiosarcoma   -      -    1      -       -    - - - - -    1   
KS    1      -    1 6   - -      17   3    - 1    29
HPT        -    -    - 1    -      1 -       -    -      - 2   
HED    -    -    -    2      1    -      -      -    -    - 3 
MPNST      1    -      -      -    -      -    - - - - 1
Liposarcoma     -    2    -    -    -      -      -    - - -    2   
Unclassified     - - - - - - - - -      1    1  
Total    26    28    7    11      1      2    17    3    1    5       
60 squamous cell 
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DISCUSSION 
Generally, maxillofacial mesenchymal malignancies 
are rare. In the present study, these neoplasms 
comprised 19% of all malignant tumours affecting 
the maxillofacial region. The results show similarity 
in the occurrence of sarcomas in the maxillofacial 
region with those seen in Kaduna, Nigeria (5), though 
these are higher than those seen in European and 
Asian populations (6,18). This may reflect a racial or 
ethnic bias with higher incidences of maxillofacial 
sarcomas seen in Black populations than among 
the Caucasian stock. In the present study, epithelial 
malignancies (carcinomas) tended to affect patients 
in the older age groups while the maxillofacial 
sarcomas afflicted younger patients. Similar patterns 
have been described in the western literature (2,4). 
This implies that genetic factors may have a more 
significant role to play than environmental influences 
in the development of maxillofacial sarcomas unlike 
carcinomas where environmental factors such as 
tobacco and alcohol usage have been implicated. 
 Sarcomas can be detected during routine 
examination for other conditions or due to non-
specific signs and symptoms. The presenting features 
of sarcomas are non-specific and depend on tumour 
location, size, rate of growth, duration and level of 
cancer awareness in the individual (1). All but one 
case seen in this study presented with swelling while 
a few had pain, mobility of teeth, bleeding from the 
tumour and trismus. Notably, one case was found 
incidentally on routine dental examination. The 
average duration of these lesions was short (mean 
9.9 months), as has been reported in other studies, 
reflecting the rapidity of growth of these lesions. 
Osteosarcoma was the most frequently diagnosed 
hard tissue malignant maxillofacial mesenchymal 
neoplasm in the present study and this is consistent 
with previous data from this country (4) as well as 
from other parts of Africa (11,25). From the literature, 
the most common sarcoma is controversial depending 
on the age group, site and possibly racial factors. 
RMS has been documented as the most common soft 
tissue oral and maxillofacial sarcoma in childhood 
(19-21) while in adults, osteosarcoma predominates 
(22-24). 
 Analysis of age and gender distribution of 
maxillofacial osteosarcomas in this study noted 
some trends. The mean ages at first presentation 
of maxillofacial osteosarcoma were consistent with 
data from other African studies (5,26) but lower 
than data from European studies (7,13,14). The 
lower mean age of occurrence of osteosarcoma is 
probably influenced by the lower age expectancy in 
the Kenyan population (52 years in 2006). From the 
literature, the average age of onset of osteosarcomas 
of the jaws and craniofacial bones has been reported 
to present ten to twenty years later than for skeletal 
lesions; and the histopathological variables are more 
favourable, distant metastases occur less· frequently 
and survival rates are higher (27 - 29). Our data also 
showed that there was no clear gender predilection. 
The marginal differences in gender predilection 
seen in the Kenyan studies infer that osteosarcoma 
may have no real preference for any gender in that 
population which is in agreement with what has been 
observed in European or American studies. 
 There is inconsistency as to the most common 
site of occurrence of osteosarcoma in the craniofacial 
region from data gathered in the African selling. 
Some authors site the mandible as the most 
afflicted (5,11,26) while others the maxilla (25). 
Nonetheless, the mandible and maxilla contribute 
disproportionately to the sites affected within the 
region (1) as was corroborated in this study. In our 
series the osteoblastic sub-type of osteosarcoma was 
the most common similar to a report by Bertoni et al. 
followed by the fibroblastic and chondroblastic sub-
types (30). However, other reports have stated that 
the chondroblastic sub-types are the most common 
(31). The chondroblastic variant has been proposed to 
be an adverse prognostic factor while the fibroblastic 
variant to have had the best prognosis (32) although 
the largest series to date failed to show any impact 
of histological sub-type on survival (33). As would 
be expected, based on evidence elsewhere (39), 
chondrosarcomas (CHS) were found to have been 
particularly rare in this series. Only two lesions had 
been diagnosed over the ten-year period. In general, 
CHS occurs more often in males, in a ratio of about 2: 
1; and there are no pathognomonic signs or symptoms 
presented (40). 
 KS has been described as one of the most common 
malignant tumours in Africa. It is the most common 
cancer associated with HIV infection, occurring in 
up to one in four AIDS patients (4). Indeed KS is 
most prevalent in countries where HIV infection is 
prevalent. In our report, KS was the second most 
common maxillofacial malignancy making up 28% 
with no clear gender predilection, as has been noted in 
more recent publications (35). It was the most common 
sarcoma of the head and neck in a report by Chindia 
et al. with a male to female ratio of 3:1 (4). The change 
in gender affliction trends noted may reflect improved 
health awareness and treatment seeking behaviour 
between both genders. The site predilection was in 
accordance with the findings of other authors with 
the palate having been the most common site (34,35). 
With the advent of the highly active anti-retroviral 
therapy (HAART), the development of KS in AIDS 
patients has decreased and this may explain the lower 
prevalence of KS in our study. 
 Among the soft tissue sarcomas, apart from KS, 
FBS was diagnosed most frequently accounting for 
18.8% of the cases. This is slightly higher than those 
reported by Chindia et al. and Adebayo et al. (4,5). In 
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this series, no clear gender predilection was noted in 
conformity with literature from other parts of Africa 
(5). However, this contrasts with a Dutch report by 
Siootweg and Muller which showed a slight female 
predominance (36). The mean ages at first diagnosis 
in this study are consistent with data from both the 
African (5) and the western literature (36). FBS occur 
in both the soft and hard tissues of the maxillofacial 
region. Siootweg and Muller assessed the lesion in 
the jaws of a Dutch population and found more in 
the mandible than the maxilla (36). Our findings 
concurred with most lesions having been found in 
the mandible (44%) and maxilla (27%) with a few 
lesions in other sites. 
 RMS was the fourth most common sarcoma 
accounting for 9.9% of all tumours reviewed which 
was similar to other African series (5,11). RMS can 
occur at any age but the lesion is most common in 
the first decade of life making it the most common 
maxillofacial sarcoma in childhood. In our series, 
50% of the neoplasms occurred in the first decade 
thereby corroborating other published series (37,38). 
RMS may be defined as a malignant tumour of the 
rhabdomyoblasts and it is estimated to comprise 12 to 
56% of all solid malignant tumours in the paediatric 
age group (37). A review by William et al found that 
among the subtypes, embryonal RMS was the most 
predominant type in the head and neck accounting 
for over half the cases with most afflicting younger 
children (38). The pleomorphic sub-type was the least 
common and was mostly found in older patients. In 
our series the pleomorphic sub-type was the most 
common followed by the embryonal sub-type, with 
one case seen of the alveolar sub-type. Lack of a 
centralised sarcoma team may have influenced the 
results seen in this study with some of the paediatric 
RMS cases having been seen by medical oncologists. 
Almost all cases were found below 30 years of age 
with one case of pleomorphic RMS occurring in the 
50-59-year-old age group. From the literature, the 
occurrence of other sarcomas in the maxillofacial 
region is rare (1, 5) and this can explain the relatively 
few cases seen in this study. 
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